| 10.00 - 12.45
5th session:
Vascular AMD
Chairmen and moderation:
Michel Eid Farah (Sao Paulo)
Norbert Bornfeld (Essen)
|
| 10.15 |
Stefan Mennel (Marburg)
Effects of PDT on the blood-retinal-barrier and
therapeutical consequences |
| 10.30 |
Salvatore Grisanti (Tübingen)
Bevacizumab (AVASTIN) ‚off-label use’ in the
therapy of neovascular ocular disorders |
| 10.45 |
Michael Ulbig (Munich)
Macugen for AMD |
| 11.00 |
Paul B. Griggs, R.C. Lee (Seattle)
Sequential pegaptanib monotherapy following verteporfin
photodynamic therapy for choroidal neovascularization |
| 11.15 |
F.B. Aggio, Michel Eid Farah, W.C. Silva, G.B. Melo
(Sao Paulo)
The Role of VEGF in vascular AMD |
| 11.30 |
Andrew A. Moshfeghi, P.J. Rosenfeld (Miami)
Ranibizumab (Lucentis) for Subfoveal Choroidal
Neovascularization (CNV) in Neovascular Age-Related
Macular Degeneration (AMD) Patients |
| 11.45 |
Stephan Michels (Vienna)
Comparing systemic to intravitreal bevacizumab (Avastin®)
in patients with neovascular AMD |
| 12.00 |
Anne Fung1, Philip J. Rosenfeld2,
Carmen Puliafito2, Stephan Michels3,
Geeta A. Lalwani2, William J. Feuer2
(1San Francisco, 2Miami, 3Vienna)
One Year Results of the PrONTO Study:
An OCT-Guided Variable-Dosing Regimen
with Ranibizumab (Lucentis™) In Neovascular
AMD |
| 12.15 |
Michel Eid Farah (Sao Paulo)
Safety of an Intravitreal Injection of Bevacizumab
(Avastin®): Results of a Multicenter Trial |
| |
|
12.30 - 13.00
Interactive panel discussion of 10 cases.
How would you treat?
Moderation:
Frank H.J. Koch (Frankfurt/M) |
|
|
|
13.00 - 13.15
Pool-lecture |
| 13.00 |
Einar Stefánsson, S.H. Hardarson, R.A. Karlsson,
G.H. Halldorsson, T. Eysteinsson, J.A. Benediktsson,
A. Thorsteinsson, P.K. Jensen, J. Beach, Einar Stefanson
(Reykjavik/Copenhagen)
Hypoxia in human BRVO improves after laser. Studies with
non-invasive automatic spectrophotometric retinal oximetry |
| |
|
| 13.15 - 14.15 |
Lunch and coffee break with the exhibitors
Cromapharma invites you for lunch. |
| |
Back to the overview |